JP2019533665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533665A5 JP2019533665A5 JP2019518989A JP2019518989A JP2019533665A5 JP 2019533665 A5 JP2019533665 A5 JP 2019533665A5 JP 2019518989 A JP2019518989 A JP 2019518989A JP 2019518989 A JP2019518989 A JP 2019518989A JP 2019533665 A5 JP2019533665 A5 JP 2019533665A5
- Authority
- JP
- Japan
- Prior art keywords
- albumin
- bioactive polypeptide
- composition
- composition according
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 108
- 229920001184 polypeptide Polymers 0.000 claims description 76
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 76
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 76
- 230000000975 bioactive effect Effects 0.000 claims description 74
- 102000009027 Albumins Human genes 0.000 claims description 72
- 108010088751 Albumins Proteins 0.000 claims description 72
- 229940079593 drug Drugs 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 48
- 239000002105 nanoparticle Substances 0.000 claims description 46
- 230000002209 hydrophobic effect Effects 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 37
- 239000007864 aqueous solution Substances 0.000 claims description 26
- 239000000839 emulsion Substances 0.000 claims description 26
- 239000003960 organic solvent Substances 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 24
- 239000003431 cross linking reagent Substances 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 14
- 238000000265 homogenisation Methods 0.000 claims description 12
- 238000001704 evaporation Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 6
- 229960000397 bevacizumab Drugs 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000004007 reversed phase HPLC Methods 0.000 claims description 4
- 229960003989 tocilizumab Drugs 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 241000549556 Nanos Species 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000010382 chemical cross-linking Methods 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 230000001268 conjugating effect Effects 0.000 claims description 2
- 238000002296 dynamic light scattering Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 230000036039 immunity Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662406367P | 2016-10-10 | 2016-10-10 | |
| US62/406,367 | 2016-10-10 | ||
| PCT/US2017/055902 WO2018071399A1 (en) | 2016-10-10 | 2017-10-10 | Nanoparticle formulations and methods of making and using thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533665A JP2019533665A (ja) | 2019-11-21 |
| JP2019533665A5 true JP2019533665A5 (enExample) | 2020-11-19 |
Family
ID=61906258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518989A Pending JP2019533665A (ja) | 2016-10-10 | 2017-10-10 | ナノ粒子製剤ならびにその作製方法および使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190247357A1 (enExample) |
| EP (1) | EP3522854A4 (enExample) |
| JP (1) | JP2019533665A (enExample) |
| KR (1) | KR20190068570A (enExample) |
| CN (1) | CN109996527A (enExample) |
| AR (1) | AR109685A1 (enExample) |
| AU (1) | AU2017343553A1 (enExample) |
| BR (1) | BR112019007087A2 (enExample) |
| CA (1) | CA3039195A1 (enExample) |
| IL (1) | IL265870A (enExample) |
| MA (1) | MA46474A (enExample) |
| MX (1) | MX2019003988A (enExample) |
| TW (1) | TW201825079A (enExample) |
| WO (1) | WO2018071399A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2117520T3 (en) | 2006-12-14 | 2019-01-07 | Abraxis Bioscience Llc | BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN |
| MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
| SI2790675T1 (sl) | 2011-12-14 | 2019-11-29 | Abraxis Bioscience Llc | Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| CN116585310A (zh) | 2015-06-29 | 2023-08-15 | 阿布拉科斯生物科学有限公司 | 治疗上皮样细胞肿瘤的方法 |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| EP4051241A4 (en) * | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
| CA3157484A1 (en) * | 2019-11-05 | 2021-05-14 | Ulagaraj Selvaraj | Nanoparticles comprising prodrugs stabilized by albumin for treatment of cancer and other diseases |
| WO2021113519A1 (en) * | 2019-12-04 | 2021-06-10 | The Trustees Of The University Of Pennsylvania | Nanoparticle compositions and methods of use |
| KR102526793B1 (ko) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법 |
| CN116889618B (zh) * | 2023-09-08 | 2023-12-01 | 四川大学华西医院 | 一种治疗糖尿病皮肤创面的药物及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62228025A (ja) * | 1985-12-27 | 1987-10-06 | Teijin Ltd | 抗体複合体の製造方法 |
| US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| CA2207961A1 (en) * | 1995-01-05 | 1996-07-11 | Robert J. Levy | Surface-modified nanoparticles and method of making and using same |
| PT1023050E (pt) * | 1997-06-27 | 2013-12-04 | Abraxis Bioscience Llc | Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização |
| CN1169827C (zh) * | 2001-08-07 | 2004-10-06 | 沈阳三生制药股份有限公司 | 一种增强多肽在体内稳定性药物的生产方法及其应用 |
| DE102004011776A1 (de) * | 2004-03-09 | 2005-11-03 | Lts Lohmann Therapie-Systeme Ag | Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen |
| WO2011057709A1 (en) * | 2009-11-13 | 2011-05-19 | Merck Patent Gmbh | Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents |
| EP2605799A4 (en) * | 2010-08-20 | 2014-02-26 | Cerulean Pharma Inc | CONJUGATES, PARTICLES, COMPOSITIONS AND RELATED METHODS |
| EP2655413B1 (en) * | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| PT2707030T (pt) * | 2011-05-09 | 2020-05-22 | Mayo Found Medical Education & Res | Tratamentos de cancro |
| EP2903610B1 (en) * | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| JP6695286B2 (ja) * | 2014-06-13 | 2020-05-20 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | リンパ腫の処置 |
| JP6600651B2 (ja) * | 2014-06-16 | 2019-10-30 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 骨髄腫の治療 |
| DK3204413T3 (da) * | 2014-10-06 | 2019-12-09 | Mayo Found Medical Education & Res | Bærerantistofsammensætninger og fremgangsmåder til fremstilling og anvendelse heraf |
-
2017
- 2017-10-10 AU AU2017343553A patent/AU2017343553A1/en not_active Abandoned
- 2017-10-10 CN CN201780072461.1A patent/CN109996527A/zh active Pending
- 2017-10-10 CA CA3039195A patent/CA3039195A1/en not_active Abandoned
- 2017-10-10 MX MX2019003988A patent/MX2019003988A/es unknown
- 2017-10-10 AR ARP170102820A patent/AR109685A1/es unknown
- 2017-10-10 EP EP17860752.9A patent/EP3522854A4/en active Pending
- 2017-10-10 MA MA046474A patent/MA46474A/fr unknown
- 2017-10-10 JP JP2019518989A patent/JP2019533665A/ja active Pending
- 2017-10-10 BR BR112019007087A patent/BR112019007087A2/pt not_active Application Discontinuation
- 2017-10-10 KR KR1020197013054A patent/KR20190068570A/ko not_active Ceased
- 2017-10-10 WO PCT/US2017/055902 patent/WO2018071399A1/en not_active Ceased
- 2017-10-10 US US16/340,676 patent/US20190247357A1/en not_active Abandoned
- 2017-10-11 TW TW106134822A patent/TW201825079A/zh unknown
-
2019
- 2019-04-07 IL IL265870A patent/IL265870A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533665A5 (enExample) | ||
| Qu et al. | Albumin nanoparticle-based drug delivery systems | |
| US10961317B2 (en) | CD20 scFv-ELPs methods and therapeutics | |
| Tan et al. | Functionalization of graphene oxide generates a unique interface for selective serum protein interactions | |
| CN116059171B (zh) | 用于将生理活性成分递送至血管的组合物 | |
| Clemments et al. | Effect of surface properties in protein corona development on mesoporous silica nanoparticles | |
| Elsabahy et al. | Data mining as a guide for the construction of cross-linked nanoparticles with low immunotoxicity via control of polymer chemistry and supramolecular assembly | |
| KR102323301B1 (ko) | Cys 연결된 항체-약물 접합체의 정제 방법 | |
| Golla et al. | Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats | |
| JP2008200039A5 (enExample) | ||
| CN112807299B (zh) | 包含多西他赛和人血清白蛋白的固体组合物及其制备方法和应用 | |
| JP2021505540A5 (enExample) | ||
| CN109996527A (zh) | 纳米颗粒制剂及其制备和使用方法 | |
| JP2019507781A5 (enExample) | ||
| JP2011519932A5 (enExample) | ||
| JP2015505559A (ja) | 治療剤送達のためのシクロデキストリン系ポリマー | |
| Abdouss et al. | Development and characterization of molecularly imprinted polymers for controlled release of citalopram | |
| RU2017129729A (ru) | Конъюгаты антитело-уреаза для терапевтических целей | |
| Paşcalău et al. | Bovine serum albumin gel/polyelectrolyte complex of hyaluronic acid and chitosan based microcarriers for Sorafenib targeted delivery | |
| Nazemian et al. | Immobilized peptide on the surface of Poly l-DOPA/silica for targeted delivery of 5-fluorouracil to breast tumor | |
| AU2007219104B2 (en) | Stable pharmaceutical composition of taxanes | |
| US20150209335A1 (en) | Methods and small molecule therapeutics comprising fused elps | |
| Saha et al. | Preclinical Development of a Genetically Engineered Albumin‐Binding Nanoparticle of Paclitaxel | |
| US20240059755A1 (en) | Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same | |
| JP2011519893A5 (enExample) |